Cited by

• Integrative proteogenomic profiling of high-risk prostate cancer samples from Chinese patients indicates metabolic vulnerabilities and diagnostic biomarkers.

  Dong B, Xu JY, Huang Y, Guo J, Dong Q, Wang Y, Li N, Liu Q, Zhang M, Pan Q, Wang H, Jiang J, Chen B, Shen D, Ma Y, Zhai L, Zhang J, Li J, Xue W, Tan M, Qin J. Dong B, et al. Nat Cancer. 2024 Sep;5(9):1427-1447. doi: 10.1038/s43018-024-00820-2. Epub 2024 Sep 6. Nat Cancer. 2024. PMID: 39242942
• Prognostic and immunological implications of heterogeneous cell death patterns in prostate cancer.

  Wang M, Dai B, Liu Q, Zhang X. Wang M, et al. Cancer Cell Int. 2024 Aug 24;24(1):297. doi: 10.1186/s12935-024-03462-7. Cancer Cell Int. 2024. PMID: 39182081 Free PMC article.
• Establishment of a prognostic risk model for prostate cancer based on Gleason grading and cuprotosis related genes.

  Wang H, Xie M, Zhao Y, Zhang Y. Wang H, et al. J Cancer Res Clin Oncol. 2024 Aug 1;150(8):376. doi: 10.1007/s00432-024-05899-9. J Cancer Res Clin Oncol. 2024. PMID: 39085482 Free PMC article.
• Autophagy-related long non-coding RNAs act as prognostic biomarkers and associate with tumor microenvironment in prostate cancer.

  Li LY, Zi H, Deng T, Li BH, Guo XP, Ming DJ, Zhang JH, Yuan S, Weng H. Li LY, et al. Am J Cancer Res. 2024 Feb 15;14(2):545-561. doi: 10.62347/XTDZ5687. eCollection 2024. Am J Cancer Res. 2024. PMID: 38455413 Free PMC article.
• Significantly reduced incidence and improved survival from prostate cancer over 25 years.

  Serdà-Ferrer BC, Sanvisens A, Fuentes-Raspall R, Puigdemont M, Farré X, Vidal-Vila A, Rispau-Pagès M, Baltasar-Bagué A, Marcos-Gragera R. Serdà-Ferrer BC, et al. BMC Public Health. 2023 Dec 21;23(1):2552. doi: 10.1186/s12889-023-17440-7. BMC Public Health. 2023. PMID: 38129873 Free PMC article.